Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

World's tallest man undergoes Gamma Knife surgery

Much of Sultan Kosen's eight feet, two-inch stature rose up in an 17-year period starting at age 10, when the benign tumor in his brain's pituitary gland highjacked the organ, causing it to secrete massive amounts of growth hormone, making Mr. Kosen's body grow fast and grow without ceasing. He will need to wait several months to find out if his Gamma Knife® surgery last Thursday at the University of Virginia (UVA, Charlottesville, Va.) has inactivated the tumor and he has reached his final height, but his physicians are optimistic.

27 Aug 2010

JVIR supplement to review thermal ablation usage in treating cancer

The unprecedented growth and promise of using thermal ablation to target and kill cancer is the subject of the Journal of Vascular and Interventional Radiology's August supplement, "Thermal Ablation 2010 At the Crossroads of Past Success, Current Goals and Future Technology."

27 Aug 2010

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

27 Aug 2010

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

In its review of the BLA, the FDA stated the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population.

27 Aug 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

Seven year Aspirin for cancer trial

A large clinical trial looking at the cancer preventive actions of aspirin is underway. The seven year study will include six regional centers from Victoria including Ballarat, Bendigo, Geelong, Warrnambool, Traralgon and Shepparton. The ASPirin for Reducing Events in the Elderly (ASPREE) study will involve about 19,000 participants from Australia and the United States.

26 Aug 2010

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Bio-Reference Laboratories, Inc. (Except for Per Share Data or where otherwise noted, numbers are in thousands) announced that the Company recorded current quarter revenues of $121,719, the best ever quarter in terms of revenues in corporate history and an increase of 25% over the $97,424 recorded in the third quarter, fiscal year 2009.

26 Aug 2010

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.

26 Aug 2010

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

Cerulean Pharma Inc., a leader in designing and developing nanopharmaceuticals, today announced that results of a Phase 1 clinical study of CRLX101 (formerly IT-101), Cerulean's lead clinical development candidate, and pre-clinical data on Cerulean's development candidate, CRLX288, were presented at the American Chemical Society National Meeting & Exposition, ongoing in Boston, Massachusetts.

26 Aug 2010

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Three-dimensional MRI is an emerging and useful technique for displaying fetal anatomy and diagnosing problems in the womb in a wide spectrum of clinical applications, according to Jeffrey C. Hellinger, M.D., a pediatric imaging specialist at Stony Brook University Medical Center.

26 Aug 2010

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

In celebration of a seminal discovery in cancer biology, Fox Chase Cancer Center will host the Philadelphia Chromosome Symposium: Past, Present and Future, on September 28, 2010, from 8 a.m. to 7 p.m. at The Chemical Heritage Foundation, 315 Chestnut Street, Philadelphia. The event marks the 50th anniversary of the discovery of the first genetic abnormality associated with cancer, and the first to lead to a targeted therapy for cancer.

25 Aug 2010

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced that the National Institute of Health/National Institute of Allergy and Infectious Disease, has awarded its research partner, the University of Rochester Medical Center (URMC), a $15 million five-year, continuation grant for studies that will utilize ImmuneRegen's Homspera.

25 Aug 2010

Varian Medical Systems enters $225M accelerated share repurchase agreement with Bank of America

Varian Medical Systems, Inc. today announced that it has entered into an agreement with Bank of America N.A. to repurchase $225 million of its common stock under an accelerated share repurchase program. Concurrently, the company amended its revolving credit facility with Bank of America N.A. to increase its borrowing capacity from $150 million to $225 million.

25 Aug 2010

Administrative Law Judge recommends grant of Certificate of Need for Trinity Medical Center's relocation

Trinity Medical Center achieved a major victory today in its effort to gain state regulatory approval for a new, state-of-the-art hospital facility on Highway 280. Administrative Law Judge (ALJ) James Hampton has issued his recommendation in favor of granting the required Certificate of Need (CON) for Trinity's relocation from its 44-year old campus on Montclair Road to the new hospital facility. The decision follows months of deliberation and a comprehensive review of the facts during what was the longest ALJ hearing on a healthcare matter in Alabama history.

25 Aug 2010

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Isotechnika Pharma Inc., a biopharmaceutical company focused on the discovery and development of immune modulating therapeutics, and 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the signing of a development and commercialization agreement for voclosporin, a next generation calcineurin inhibitor being developed for use in the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.

25 Aug 2010

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

The double-blind, placebo-controlled, parallel-group study (Study 306) showed that perampanel was well-tolerated and effective in reducing median seizure frequency and increasing responder rates, the primary outcome measures in the United States and European Union, respectively. The findings were highly statistically significant in 4 mg and 8 mg doses compared to placebo.

25 Aug 2010

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

25 Aug 2010

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced plans to seek additional government funding for development of its novel, once-daily antibiotic, Restanza.

25 Aug 2010

BioScale installs ViBE analytical tool at Massachusetts-based pharmaceutical company

BioScale Inc., an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, today announced the first shipment and installation of the ViBE™ Protein Analysis Workstation at a major Massachusetts-based pharmaceutical company.

25 Aug 2010

American Medical Group Association to participate in COPD care management

The American Medical Group Association (AMGA) and the American Medical Group Foundation (AMGF) are pleased to announce an opportunity for AMGA members to participate in a learning collaborative on care management for patients with COPD. The Best Practices Learning Collaborative is for organizations that are striving to improve the care of patients with COPD.

25 Aug 2010

Oncology News and Research

Further Reading

World's tallest man undergoes Gamma Knife surgery

JVIR supplement to review thermal ablation usage in treating cancer

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

Seven year Aspirin for cancer trial

Bio-Reference Laboratories third-quarter revenues increase 25% to $121,719

Data from PLX4032 Phase 1 clinical trial in melanoma patients with BRAF mutation published

Phase 1 CRLX101 clinical study paves way for promising innovations in cancer therapy: Cerulean Pharma

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Fox Chase Cancer Center to host Philadelphia Chromosome Symposium

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

Varian Medical Systems enters $225M accelerated share repurchase agreement with Bank of America

Administrative Law Judge recommends grant of Certificate of Need for Trinity Medical Center's relocation

3Sbio, Isotechnika Pharma sign development and commercialization agreement for voclosporin inhibitor

Eisai's Phase III trial of Perampanel for epilepsy shows positive results

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Advanced Life Sciences seeks government funding for development of Restanza antibiotic

BioScale installs ViBE analytical tool at Massachusetts-based pharmaceutical company

American Medical Group Association to participate in COPD care management

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News